Tradestie Institutional Equity Comparison Engine

ANNX vs ALXO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ANNX Overall Edge

ANNX Captures Institutional Edge (2โ€“0 Pillars ยท 4โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Annexon, Inc. Common Stock (ANNX) driven by superior Momentum & Technical, Options & Structure. Fundamentally, ANNX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ALXO at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, ANNX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against ALXO sits in BREAKDOWN (36th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ANNX N/M vs ALXO N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner ANNX
1Y +28.6% vs -27.2% ยท 52W Pos 18% vs 8%
Options & Structure Winner ANNX
BREAKDOWN (100th %ile IV) vs BREAKDOWN (36th %ile IV)
ANNX NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.48
-2.38% 1D
Market Cap $747.8M
1M Return -13.09%
1Y Return +28.6%
Forward P/E N/M
Unified AI Score
43.5 / 100 HOLD
Tech 37.0 Fund 55.0 Flow 72.0 Mom 60.0
ALXO NASDAQ
ALX Oncology Holdings Inc. Common Stock
Pharmaceutical Preparations
$1.00
+0.5% 1D
Market Cap $143.8M
1M Return -11.84%
1Y Return -27.17%
Forward P/E N/M
Unified AI Score
54.1 / 100 HOLD
Tech 45.0 Fund 57.0 Flow 66.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ANNX +28.6% ALXO -27.17% Spread: +55.77 pp (ANNX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ANNX TTM Op. Margin: 0.0% ALXO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANNX vs ALXO. Trailing 12-month operating profitability (ANNX 0.0% vs ALXO 0.0%) and valuation multiples (ANNX N/M vs ALXO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ANNX (4) vs ALXO (2)
Institutional Metric ANNX ALXO Criterion Row Winner
Market Capitalization Scale $747.8M $143.8M Larger Scale ANNX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -100.0% Higher Growth ANNX
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -130.8% -80.7% Higher ROE ALXO
52-Week Range Position Momentum 18% ($3โ€“$7) 8% ($1โ€“$3) Stronger Trend ANNX
Beta / 30D Volatility Risk Regime 1.69ฮฒ ยท 63% Vol 1.39ฮฒ ยท 111% Vol Lower Realized Risk ANNX
Unified Institutional Score Composite Signal 43.5 / 100 (HOLD) 54.1 / 100 (HOLD) Higher Composite ALXO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ANNX vs ALXO Buy Guide
ANNX BREAKDOWN
88d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live ANNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ALXO BREAKDOWN
94d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 36th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ALXO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ANNX nor ALXO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.